Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › tremelimumab

tremelimumab

1 published article · Updated continuously

Clinical Trial Landscape

Clinical Trials of tremelimumab

38 trials tracked of tremelimumab: 1 in phase 3 or 4 and 1 with published results. The most-cited published study has 18 citations.

38Trials tracked
1Phase 3 & 4
0Recruiting
1With published results
Phase distribution
Phase 3 1 Phase 2 30 Phase 1 5 Other / NA 2
  1. Phase 3 Phase III Open Label Study of MEDI 4736 With/Without Tremelimumab Versus Standard of Care (SOC) in Recurrent/Metastatic Head and Neck Cancer Completed · 18 cited
  2. Phase 2 A Study of Tremelimumab and IV Durvalumab Plus Poly-ICLC in Subjects With Biopsy-accessible Cancers Completed
  3. Phase 2 Immune-Modulated Study of Selected Small Molecules (Gefitinib, AZD9291, or Selumetinib + Docetaxel) or a 1st Immune-Mediated Therapy (IMT; Tremelimumab) With a Sequential Switch to a 2nd IMT (MEDI4736) in Patients With Locally Advanced or Metastatic Non-Small-Cell Lung Cancer Completed
  4. Phase 2 Study of Durvalumab and Tremelimumab After Radiation for Microsatellite Stable Metastatic Colorectal Cancer Progressing on Chemotherapy Completed
  5. Phase 2 Olaparib, Durvalumab, and Tremelimumab in Treating Patients With Recurrent or Refractory Ovarian, Fallopian Tube or Primary Peritoneal Cancer With BRCA1 or BRCA2 Mutation Completed
  6. Phase 2 A Pilot Study of Combined Immune Checkpoint Inhibition in Combination With Ablative Therapies in Subjects With Hepatocellular Carcinoma (HCC) or Biliary Tract Carcinomas (BTC) Completed
Show 32 more trials
  1. Phase 2 Trial of Tremelimumab in Patients With Previously Treated Metastatic Urothelial Cancer Completed
  2. Phase 2 Phase II Study of MEDI4736, Tremelimumab, and MEDI4736 in Combination w/ Tremelimumab Squamous Cell Carcinoma of the Head and Neck Completed
  3. Phase 2 Durvalumab With or Without Tremelimumab in Metastatic Castration Resistant Prostate Cancer Completed
  4. Phase 2 Durvalumab (MEDI4736) Plus Tremelimumab for Advanced Neuroendocrine Neoplasms of Gastroenteropancreatic or Lung Origin Completed
  5. Phase 2 Tremelimumab With Chemoembolization or Ablation for Liver Cancer Completed
  6. Phase 2 Gemcitabine and Nab-Paclitaxel vs Gemcitabine, Nab-Paclitaxel, Durvalumab and Tremelimumab as 1st Line Therapy in Metastatic Pancreatic Adenocarcinoma Completed
  7. Phase 2 Immune Checkpoint Inhibition (Tremelimumab and/or MEDI4736) in Combination With Radiation Therapy in Patients With Unresectable Pancreatic Cancer Completed
  8. Phase 2 Study of Anti-PD-L1 in Combination With Chemo(Radio)Therapy for Oesophageal Cancer Completed
  9. Phase 2 A Study of Durvalumab With or Without Tremelimumab in Endometrial Cancer Completed
  10. Phase 2 Durvalumab and Tremelimumab in Patients With Advanced Rare Tumours Completed
  11. Phase 2 GSK3359609 Plus Tremelimumab for the Treatment of Advanced Solid Tumors Completed
  12. Phase 2 Phase 1/2 Study of Combination Immunotherapy and Messenger Ribonucleic Acid (mRNA) Vaccine in Subjects With NSCLC Completed
  13. Phase 2 Durvalumab and Tremelimumab and Best Supportive Care vs Best Supportive Care in Patients With Advanced Colorectal Cancer Completed
  14. Phase 2 A Phase I/II Study of Pexa-Vec Oncolytic Virus in Combination With Immune Checkpoint Inhibition in Refractory Colorectal Cancer Completed
  15. Phase 2 Multi-Arm Study to Test the Efficacy of Immunotherapeutic Agents in Multiple Sarcoma Subtypes Completed
  16. Phase 2 Durvalumab Plus Tremelimumab With Concurrent Radiotherapy for Localized Muscle Invasive Bladder Cancer Treated With a Selective Bladder Preservation Approach Completed
  17. Phase 2 Durvalumab and Tremelimumab in Treating Patients With Recurrent Stage IV Lung Cancer Completed
  18. Phase 2 MEDI4736 and Tremelimumab in Treating Patients With Metastatic HER2 Negative Breast Cancer Completed
  19. Phase 2 Tremelimumab and Durvalumab in Combination or Alone in Treating Patients With Recurrent Malignant Glioma Completed
  20. Phase 2 A Phase 1b/2 Study of MEDI4736 With Tremelimumab, MEDI4736 or Tremelimumab Monotherapy in Gastric or GEJ Adenocarcinoma Completed
  21. Phase 2 CTLA-4 /PD-L1 Blockade Following Transarterial Chemoembolization (DEB-TACE) in Patients With Intermediate Stage of HCC (Hepatocellular Carcinoma) Using Durvalumab and Tremelimumab Completed
  22. Phase 2 A Clinical Trial of Durvalumab and Tremelimumab, Administered With Radiation Therapy or Ablation in Patients With Colorectal Cancer Completed
  23. Phase 2 Tremelimumab and Durvalumab With or Without Radiation Therapy in Patients With Relapsed Small Cell Lung Cancer Completed
  24. Phase 2 Durvalumab and Tremelimumab in Treating Chemotherapy Naive Patients With Metastatic Castration-Resistant Prostate Cancer Completed
  25. Phase 2 MEDI4736 Or MEDI4736 + Tremelimumab In Surgically Resectable Malignant Pleural Mesothelioma Completed
  26. Phase 1 A Phase 1 Study to Evaluate MEDI4736 in Combination With Tremelimumab Completed
  27. Phase 1 Oral Decitabine (ASTX727) and Durvalumab in Recurrent and/or Metastatic Head and Neck Cancer Patients Completed
  28. Phase 1 Tremelimumab and Durvalumab in Treating Patients With Colorectal Cancer With Liver Metastases That Can Be Removed by Surgery Completed
  29. Phase 1 Durvalumab and Tremelimumab Before Surgery in Treating Patients With Hormone Receptor Positive, HER2 Negative Stage II-III Breast Cancer Completed
  30. Phase 1 A Study of LY3022855 in Combination With Durvalumab or Tremelimumab in Participants With Advanced Solid Tumors Completed
  31. N/A Brain Irradiation and Tremelimumab in Metastatic Breast Cancer Completed
  32. N/A Lung-MAP: Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer Completed

Showing the 38 most-cited and recently-updated of 38 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Narrative review explores CSF1R inhibitor potential in pediatric medulloblastoma precision immunotherapy
Diabetes & Endocrinology Sys. Review
Narrative review explores CSF1R inhibitor potential in pediatric medulloblastoma precision immunotherapy The Hidden Reason Children's Brain Tumors Respond So Differently to Treatment
This narrative review examines the role of CSF1R inhibitors as precision immunotherapy for pediatric medulloblastoma subtypes.
Each subtype of children's brain tumors has a unique immune fingerprint, meaning matching treatment to that specific environment could drama…
Frontiers Apr 18, 2026